Three Filings Planned, Two Others On Track – But No Names From Viatris
Continuing Investment In Complex And Value-Added Products Despite Novel Focus
Viatris’ CEO-in-waiting Scott Smith introduced himself during Viatris’ year-end earnings call.
You may also be interested in...
Three Years After US Filing, Biocon’s Bevacizumab Remains Out Of Reach
Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.
Infringement Order Blocks Viatris’ US Symbicort Rival Until July 2023
After a string of victories, Viatris has fallen to AstraZeneca’s US Symbicort intellectual property, pushing back its planned generic launch by half a year.
Biocon Closes $3bn Deal For Viatris Biosimilars
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.